By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
When people are impacted by diseases, they deserve the best possible treatment. Thanks to the development of innovative medicines, it is possible to achieve increasingly better treatment outcomes for them.
With a 40-year history, Amgen is dedicated to developing innovative and effective biologics and biosimilars for people with serious diseases. Our product portfolio covers diverse therapeutic areas, including oncology, hematology, cardiovascular disease, osteoporosis and inflammatory diseases. With our medicines we reach more than 10 million patients in approximately 100 countries worldwide.
Since 1997 our facility in Breda, Amgen Europe, plays a crucial role. This is where our medicines are labeled, packaged, and distributed throughout Europe and a growing number of countries in other parts of the world. The Dutch commercial and medical organization is also located in Breda and ensures the availability of our medicines and clinical trials in the Netherlands.
To further improve the lives of people with serious diseases, we also collaborate with other parties on various solutions that enable appropriate care (passende zorg). Our innovations focus on patients with diseases for which no or few treatment options yet exist. In doing so, the quality of life of individuals is paramount. This is how Amgen works every day to improve patient care.
In Amgen Breda we produce and distribute medicines throughout Europe and a growing number of countries in other parts of the world. But we do much more. Here is an impression of what happens inside Amgen Breda!
Welcome to Amgen a multifunctional site that is integrated capabilities to support engines global expansion. Annually the multi-language customer success department handles more than 450,000 orders from around the world; the planning department makes an optimal efficient production schedule ensuring that the patients receive their medicines on time. Patients and health care professionals need to be able to read the information about the product in their local language a dedicated artwork department is equipped to design artwork in multiple languages carefully checked for quality. All components are received in the internal distribution center before release to production the components are checked by the quality department. Based on the production schedule all components are prepared for final packaging. The site's agile production facility assembles labels and packs around 25 million units annually fully automated for large production orders semi automated and manual for smaller production orders. All according to country specific requirements.
Returning to our distribution center the products are now ready for final shipment around the globe. After a final quality check is done Amgen products are released ot he market. A global supply chain organization reaching Europe and Intercontinental ensure the supply of Amgen products to the world. The Breda site supports Amgen's clinical trials the clinical operations department is responsible for setting up customized supply chain solutions for all Amgen studies conducted in 57 countries across the globe. Clinical customer service ensures timely delivery to clinical sites and 22 depot’s across the globe closely partnering with the Breda distribution team. The international operations Information Systems organization and the finance and global business services organization provides supporting services to Amgen entities in Europe and beyond.
Breda is also home to the Netherlands affiliate. Main activities are focused on clinical research and servicing patients in the Dutch market. Clinical research is vital for Amgen's mission to serve patients the Netherlands is a key country for Amgen's clinical research program to develop new drugs for the future The focus of the commercial department is to collaborate with healthcare professionals and key stakeholders on the optimal way to use Amgens’ products and to provide them added value services ensuring that we deliver successful treatments to patients.
Amgen Breda collaborating to serve patients around the world.
Amgen was one of the pioneering companies in the use of living cells to manufacture biological medicines, opening the way to the field of biotechnology: we created and gave visibility to the scientific and productive procedures that turned biotechnology into a source of therapies for patients. Worldwide.
At Amgen we develop innovative medicines for significant unmet medical needs focused on several therapeutic areas: oncology, hematology, bone health, inflammation, cardiovascular disease, neurology, and nephrology.
We have a robust portfolio of innovative medicines, and important projects underway, to lead the next generation in bio-manufacturing. Our research focuses on the study of innovative molecules, new indications for various drugs and biosimilar treatments.
For more than 40 years, with a passion for biology and technology, we have been building our expertise in drug discovery, development and delivery. Read here how we started and grew into one of the largest independent biotech companies in the world.